Cargando…
Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagu...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553987/ https://www.ncbi.nlm.nih.gov/pubmed/34722585 http://dx.doi.org/10.3389/fmed.2021.747527 |
_version_ | 1784591694465859584 |
---|---|
author | Smadja, David M. Bonnet, Guillaume Gendron, Nicolas Weizman, Orianne Khider, Lina Trimaille, Antonin Mirault, Tristan Fauvel, Charles Diehl, Jean-Luc Mika, Delphine Philippe, Aurelien Pezel, Théo Goudot, Guillaume Sutter, Willy Planquette, Benjamin Waldmann, Victor Sanchez, Olivier Cohen, Ariel Chocron, Richard |
author_facet | Smadja, David M. Bonnet, Guillaume Gendron, Nicolas Weizman, Orianne Khider, Lina Trimaille, Antonin Mirault, Tristan Fauvel, Charles Diehl, Jean-Luc Mika, Delphine Philippe, Aurelien Pezel, Théo Goudot, Guillaume Sutter, Willy Planquette, Benjamin Waldmann, Victor Sanchez, Olivier Cohen, Ariel Chocron, Richard |
author_sort | Smadja, David M. |
collection | PubMed |
description | Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagulation (AC) among patients with COVID-19 hospitalized in medical wards. Methods and results: We used a large French multicentric retrospective study enrolling 2,878 COVID-19 patients hospitalized in medical wards. After exclusion of patients who had an AC treatment before hospitalization, we generated a propensity-score-matched cohort of patients who were treated with intermediate-dose or standard-dose prophylactic AC between February 26 and April 20, 2020 (intermediate-dose, n = 261; standard-dose prophylactic anticoagulation, n = 763). The primary outcome of the study was in-hospital mortality; this occurred in 23 of 261 (8.8%) patients in the intermediate-dose group and 74 of 783 (9.4%) patients in the standard-dose prophylactic AC group (p = 0.85); while time to death was also the same in both the treatment groups (11.5 and 11.6 days, respectively, p = 0.17). We did not observe any difference regarding venous and arterial thrombotic events between the intermediate dose and standard dose, respectively (venous thrombotic events: 2.3 vs. 2.4%, p=0.99; arterial thrombotic events: 2.7 vs. 1.2%, p = 0.25). The 30-day Kaplan–Meier curves for in-hospital mortality demonstrate no statistically significant difference in in-hospital mortality (HR: 0.99 (0.63–1.60); p = 0.99). Moreover, we found that no particular subgroup was associated with a significant reduction in in-hospital mortality. Conclusion: Among COVID-19 patients hospitalized in medical wards, intermediate-dose prophylactic AC compared with standard-dose prophylactic AC did not result in a significant difference in in-hospital mortality. |
format | Online Article Text |
id | pubmed-8553987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85539872021-10-30 Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study Smadja, David M. Bonnet, Guillaume Gendron, Nicolas Weizman, Orianne Khider, Lina Trimaille, Antonin Mirault, Tristan Fauvel, Charles Diehl, Jean-Luc Mika, Delphine Philippe, Aurelien Pezel, Théo Goudot, Guillaume Sutter, Willy Planquette, Benjamin Waldmann, Victor Sanchez, Olivier Cohen, Ariel Chocron, Richard Front Med (Lausanne) Medicine Background: Microthrombosis and large-vessel thrombosis are the main triggers of COVID-19 worsening. The optimal anticoagulant regimen in COVID-19 patients hospitalized in medical wards remains unknown. Objectives: To evaluate the effects of intermediate-dose vs. standard-dose prophylactic anticoagulation (AC) among patients with COVID-19 hospitalized in medical wards. Methods and results: We used a large French multicentric retrospective study enrolling 2,878 COVID-19 patients hospitalized in medical wards. After exclusion of patients who had an AC treatment before hospitalization, we generated a propensity-score-matched cohort of patients who were treated with intermediate-dose or standard-dose prophylactic AC between February 26 and April 20, 2020 (intermediate-dose, n = 261; standard-dose prophylactic anticoagulation, n = 763). The primary outcome of the study was in-hospital mortality; this occurred in 23 of 261 (8.8%) patients in the intermediate-dose group and 74 of 783 (9.4%) patients in the standard-dose prophylactic AC group (p = 0.85); while time to death was also the same in both the treatment groups (11.5 and 11.6 days, respectively, p = 0.17). We did not observe any difference regarding venous and arterial thrombotic events between the intermediate dose and standard dose, respectively (venous thrombotic events: 2.3 vs. 2.4%, p=0.99; arterial thrombotic events: 2.7 vs. 1.2%, p = 0.25). The 30-day Kaplan–Meier curves for in-hospital mortality demonstrate no statistically significant difference in in-hospital mortality (HR: 0.99 (0.63–1.60); p = 0.99). Moreover, we found that no particular subgroup was associated with a significant reduction in in-hospital mortality. Conclusion: Among COVID-19 patients hospitalized in medical wards, intermediate-dose prophylactic AC compared with standard-dose prophylactic AC did not result in a significant difference in in-hospital mortality. Frontiers Media S.A. 2021-10-15 /pmc/articles/PMC8553987/ /pubmed/34722585 http://dx.doi.org/10.3389/fmed.2021.747527 Text en Copyright © 2021 Smadja, Bonnet, Gendron, Weizman, Khider, Trimaille, Mirault, Fauvel, Diehl, Mika, Philippe, Pezel, Goudot, Sutter, Planquette, Waldmann, Sanchez, Cohen and Chocron. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Smadja, David M. Bonnet, Guillaume Gendron, Nicolas Weizman, Orianne Khider, Lina Trimaille, Antonin Mirault, Tristan Fauvel, Charles Diehl, Jean-Luc Mika, Delphine Philippe, Aurelien Pezel, Théo Goudot, Guillaume Sutter, Willy Planquette, Benjamin Waldmann, Victor Sanchez, Olivier Cohen, Ariel Chocron, Richard Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study |
title | Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study |
title_full | Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study |
title_fullStr | Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study |
title_full_unstemmed | Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study |
title_short | Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study |
title_sort | intermediate- vs. standard-dose prophylactic anticoagulation in patients with covid-19 admitted in medical ward: a propensity score-matched cohort study |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553987/ https://www.ncbi.nlm.nih.gov/pubmed/34722585 http://dx.doi.org/10.3389/fmed.2021.747527 |
work_keys_str_mv | AT smadjadavidm intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT bonnetguillaume intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT gendronnicolas intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT weizmanorianne intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT khiderlina intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT trimailleantonin intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT miraulttristan intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT fauvelcharles intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT diehljeanluc intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT mikadelphine intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT philippeaurelien intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT pezeltheo intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT goudotguillaume intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT sutterwilly intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT planquettebenjamin intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT waldmannvictor intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT sanchezolivier intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT cohenariel intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy AT chocronrichard intermediatevsstandarddoseprophylacticanticoagulationinpatientswithcovid19admittedinmedicalwardapropensityscorematchedcohortstudy |